FDA approves gefurulimab for myasthenia gravis
-
By
-
Mouj Hijazi
-
November 16, 2026
-
3 min
Clinical Scorecard: FDA approves gefurulimab for myasthenia gravis
At a Glance
| Category | Detail |
|---|---|
| Condition | Clinical topic addressed by the source article: FDA approves gefurulimab for myasthenia gravis |
| Key Mechanisms | Mechanisms or clinical associations described in the source article. |
| Target Population | Population described in the source article. |
| Care Setting | FDA-approved treatment administered subcutaneously once weekly; patients or caregivers may administer it after appropriate training. Access is through a restricted REMS. |
Key Highlights
- The FDA approved gefurulimab-gaks (Klygefa) for adults with AChR antibody-positive gMG.
- In the 26-week PREVAIL trial, MG-ADL scores improved by 4.2 points with gefurulimab and 2.6 points with placebo; the treatment difference was −1.6 points.
- The key secondary endpoint, Quantitative Myasthenia Gravis score, improved by 4.5 points with gefurulimab and 2.4 points with placebo.
- The approved regimen uses a weight-based loading dose followed by weekly subcutaneous dosing.
- The prescribing information includes a boxed warning for serious meningococcal infections and requires meningococcal vaccination and REMS participation.
Guideline-Based Recommendations
Diagnosis
- FDA approval is for adults with AChR antibody-positive gMG.
Management
- For patients weighing less than 80 kg, administer 600 mg on day 1, then 300 mg once weekly starting on day 8.
- For patients weighing 80 kg or more, administer 900 mg on day 1, then 600 mg once weekly starting on day 8.
- Patients or caregivers may administer treatment after appropriate training.
- Gefurulimab is available only through a REMS requiring prescriber certification, patient counseling, and vaccination assessment.
Monitoring & Follow-up
- Assess meningococcal vaccination status before treatment; the prescribing information requires vaccination at least 2 weeks before treatment, with antibacterial prophylaxis when urgent treatment is necessary in patients not up to date with vaccination.
- The PREVAIL primary endpoint was change from baseline in MG-ADL total score at week 26.
Risks
- The boxed warning addresses serious meningococcal infections.
- Do not initiate treatment in patients with unresolved serious Neisseria meningitidis infection.
- If urgent treatment is needed in a patient not up to date with meningococcal vaccination, antibacterial prophylaxis is required.
- In PREVAIL, injection-site reactions occurred in 12% of gefurulimab recipients versus 3% with placebo; back pain in 8% versus 2%; and vomiting in 5% versus 1%.
Patient & Prescribing Data
FDA-approved for adults with AChR antibody-positive gMG. PREVAIL enrolled 260 adults with MGFA class II–IV disease and MG-ADL scores of at least 5; participants continued eligible background therapies at stable doses.
In PREVAIL, 65.5% of gefurulimab recipients achieved at least a 3-point MG-ADL improvement at week 26, compared with 52.2% receiving placebo. AstraZeneca reported improvement beginning at week 1 and maintained through week 26.
Clinical Best Practices
- Prescribing-information requirement: assess meningococcal vaccination status and vaccinate at least 2 weeks before treatment; use antibacterial prophylaxis when urgent treatment is necessary for a patient not up to date with vaccination.
- Do not initiate gefurulimab in patients with unresolved serious Neisseria meningitidis infection.
- Complete REMS requirements, including prescriber certification, patient counseling, and vaccination assessment.
Related Resources & Content
Based on findings from:
FDA approves gefurulimab for myasthenia gravis
Mouj Hijazi. MDSpire News, 2026.
https://news.mdspire.com/neurology/articles/fda-approves-gefurulimab-for-myasthenia-gravis/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.